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Purpose: There is growing evidence that glutamatergic signaling may be involved in major 
depressive disorder (MDD). In regard to peripheral blood glutamate changes in MDD, incon-
sistent findings have been reported. The purpose of the present study was to evaluate whether 
blood glutamate levels differed between MDD patients and control participants.
Materials and methods: We conducted a systematic review and meta-analysis of 12 asso-
ciation studies between blood glutamate levels and MDD in a total of 529 MDD patients and 
590 controls. Subsequently, we conducted subgroup analyses and a meta-regression analysis 
to examine the sources of potential heterogeneity.
Results: A random effects model showed that blood glutamate levels were significantly higher 
in MDD patients than in controls (standardized mean difference=0.54, 95% CI=0.27–0.82, 
p=8.5×10-5) with high heterogeneity (I2=75.0%, p,0.05). Subgroup analyses showed elevated 
glutamate levels in MDD patients compared with controls in plasma, but not serum studies, 
and in studies using high-performance liquid chromatography but not with mass spectrometry 
for glutamate assay. A meta-regression analysis showed no effects of age, gender, medication 
use, sample size, and published year on blood glutamate levels.
Conclusion: Our findings suggest that altered glutamate levels may be implicated in MDD, 
which provides further evidence of glutamatergic dysfunction in MDD.
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Introduction
Major depressive disorder (MDD) is a common neuropsychiatric disorder with high 
prevalence.1 Several pathophysiological mechanisms have been proposed to underlie 
this disorder, such as altered monoamines, increased inflammation, and abnormalities 
of the hypothalamic–pituitary–adrenal axis.2,3
There is growing evidence that glutamatergic signaling may be involved in 
the pathophysiology of MDD.4–6 Dysregulation between the main excitatory 
glutamatergic and inhibitory gamma-aminobutyric acid-ergic neurotransmission 
results in cellular damage called “excitotoxicity,” and this phenomenon is thought 
to be the cause of MDD.7 Glutamate is one of the major excitatory amino acid 
neurotransmitters. It plays a major role in brain development, affecting neuronal 
migration, neuronal differentiation, axon genesis, and neuronal survival.5 Under 
normal conditions, glutamate has a prominent role in synaptic plasticity, learning, 
and memory, while it is also known to be a potent neuronal excitotoxin, triggering 
either rapid or delayed neurotoxicity in pathological conditions.4 Further, gluta-
mate neurotoxicity results from excessive flux of Ca2 via ionotropic receptors, 
and uncontrolled elevation of intracellular Ca2 leads to a cascade of events that 
contribute to cell damage and death.8 Glutamate may also play an important role 
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in the treatment of MDD.9,10 For example, a significant 
decrease in blood glutamate levels has been observed in 
MDD after treatment with antidepressants.11,12 In a recent 
meta-analysis of 6 randomized, double-blind, and placebo-
controlled trials of ketamine, an N-methyl-d-aspartate 
glutamate receptor antagonist, a rapid antidepressant 
action of ketamine was observed for MDD during 1 week 
period.13 Moreover, a number of studies have shown 
antidepressant-like effects of glutamatergic agents on 
behavioral models of MDD.10
Recently, we demonstrated elevated plasma glutamate 
levels in individuals with MDD, using capillary electrophoresis-
time-of-flight mass spectrometry.14 However, with regard to 
peripheral blood glutamate levels in MDD, inconsistent 
findings have been reported. Although some clinical studies 
have shown elevated plasma or serum levels of glutamate in 
MDD,11,14–19 others did not observe any differences between 
MDD patients and control subjects.12,20–24 Besides, it is still 
unclear whether peripheral blood glutamate levels can reflect 
brain glutamate levels, since inconsistent findings of central 
and peripheral glutamate levels in MDD have been reported. 
A previous postmortem brain study reported increased levels 
of glutamate in the frontal cortex of patients with MDD.25 One 
previous study demonstrated increased levels of glutamate 
in the occipital cortex in MDD by using proton magnetic 
resonance spectroscopy,26 while a recent meta-analysis of 
proton magnetic resonance spectroscopy studies showed no 
change in glutamate levels in the prefrontal cortex in MDD 
along with decreased levels of glutamate and glutamine 
combined.27 Another study demonstrated increased levels of 
glutamate in the cerebrospinal fluid in depressed patients,28 
whereas other studies have reported decreased levels or no 
significant differences.29–31
In this study, we conducted a systematic review and 
meta-analysis of association studies to evaluate whether 
peripheral blood glutamate levels differed between MDD 
patients and controls.
Materials and methods
study selection process for a meta-
analysis
Eligible studies were identified in September 2017 with 
PubMed and Scopus databases, using the keywords (“Major 
depressive disorder” OR “depression” OR “depressive 
disorder”) AND (“glutamate” OR “glutamic acid”) AND 
(“serum” OR “plasma”). We also conducted an addi-
tional manual search of reference lists in the included 
publications. Studies meeting the following criteria were 
included for further meta-analysis: 1) studies assessing 
peripheral blood (serum or plasma) glutamate levels; 
2) studies comparing glutamate levels in MDD patients 
and control subjects; and 3) studies written in English. 
Three reviewers (Inoshita M, Tomioka Y, and Watanabe 
SY) selected the articles independently according to the 
inclusion criteria. The flow chart of the present study’s 
selection is shown in Figure S1.
Data extraction
The following data were extracted from eligible studies: 
ethnicity, sample size, gender distribution, mean age, mean 
glutamate concentrations and SD, unit of measure, blood 
sampling, glutamate assay, medication use, and diagnostic 
criteria.
statistical methods
Statistical analyses were performed with the “metafor” pack-
age in R (version 3.2.3). A meta-analysis of association stud-
ies was performed on standardized mean differences (SMD) 
using the data of sample size and mean and SD of glutamate 
concentration.32,33 When the data were presented as a sub-
group, we combined these data into one group and calculated 
the composite mean using the formula: Composite mean 
= ⋅= (n( ) M( ))/N,1 i ii
k∑  where n(i) was the sample size of ith 
group, M(i) was the mean of ith group, k was the number of 
groups, and N was the overall sample size; and composite 
variance using the formula: Composite variance = (ess+gss)/
(N-1), where ess was the overall error sum of squares and gss 
was the overall group sum of squares. When the data were 
presented as median and interquartile range, we calculated 
the mean and SD.34 When the data were presented with 
standard error (SE) of the mean, we calculated the SD as 
√n×SE, where n was the sample size. Heterogeneity across 
studies was quantified with the I2 statistic, with 25%, 50%, 
and 75% indicating small, moderate, and high levels of 
heterogeneity, respectively.35 If heterogeneity across studies 
was found, then an inverse-weight variance random-effects 
model was applied; otherwise, a fixed-effects model was 
applied. Publication bias was assessed using a regression test 
for funnel plot asymmetry.36 The influence of each selected 
study on the outcome was assessed using a leave-one-out 
sensitivity analysis.37 Subgroup analyses were performed on 
the basis of blood sampling (plasma or serum), glutamate 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Blood glutamate levels were significantly higher in MDD patients
mass spectroscopy), medication use, fasting or nonfasting 
sample, and ethnicity (Asian or non-Asian). Meta-regression 
analysis was performed to examine the effects of age, gender 
(% male), medication exposure (% medication-received 
patients), sample size, and published year.
Results
Meta-analysis
Eleven studies met our inclusion criteria for our meta-
analysis12,14,15–22,24 (Figure S1), and the characteristics of 
these 11 studies are shown in Table 1. Among the 11 studies, 
6 studies reported elevated glutamate levels in MDD,14,15–19 
and the other 5 studies did not find significant differences 
in glutamate levels between MDD patients and control 
subjects.12,20–22,24
When we conducted a meta-analysis of these 12 asso-
ciation studies between blood glutamate levels and MDD 
from 11 studies in a total of 529 patients with MDD and 
590 control participants, a random effects model showed 
that blood glutamate levels were significantly higher in 
patients with MDD than in controls, with high heterogeneity 
(SMD=0.54, 95% CI=0.27–0.82, p=8.5×10-5, I2=75.0%, 
p,0.05, Figure 1). A funnel plot analysis indicated no 
evidence of publication bias in the association studies 
(p.0.05, Figure 2). A leave-one-out sensitivity analysis 
indicated our result was not driven by any single study 
(p,0.05, Table S1).
subgroup analyses
We conducted subgroup analyses according to blood 
sampling, glutamate assay, medication use, fasting or 
nonfasting sample, and ethnicity (Table 2). The pooled 
SMD from 10 plasma14,15–22 and 2 serum studies12,24 was 
0.62 (95% CI=0.31–0.93, p=1.0×10-4, I2=75.9%, p,0.05) 
and 0.16 (95% CI=-0.12–0.45, p=0.26, I2=0%, p=0.42), 
respectively. The pooled SMD from 8 studies using HPLC 
assay12,15–17,19–20,22,24 and 4 studies using MS14,18,19,21 was 0.41 
(95% CI=0.22–0.60, p,1.0×10-4, I2=28.5%, p=0.22) and 
0.69 (95% CI=-0.069–1.45, p=0.075, I2=89.7%, p,0.05), 
respectively. The pooled SMD from 8 studies using medica-
tion-free samples12,14–16,18,20–22 was 0.59 (95% CI=0.19–1.00, 
p=4.0×10-3, I2=72.9%, p,0.05). The pooled SMD from 
4 studies using fasting samples16,18,21,22 and 3 studies using non-
fasting samples14,19 was 0.33 (95% CI=0.063–0.59, p=0.015, 
I2=0%, p=0.51) and 0.90 (95% CI=0.031–1.77, p=0.042, 
I2=94.1%, p,0.05), respectively. The pooled SMD from 
7 Asian studies14,17–19,21,24 and 5 non-Asian studies12,15,16,20,22 
was 0.58 (95% CI=0.14–1.02, p=0.01, I2=88.6%, p,0.05) 
and 0.48 (95% CI=0.21–0.76, p=6.0×10-4, I2=0%, p=0.84), 
respectively.
Meta-regression analysis
When we conducted a meta-regression analysis to examine 
the effects of age, gender, medication use, sample size, and 
published year on the glutamate levels, we found no effects 
of these variables on blood glutamate levels ( p.0.05) 
(Table 3).
Discussion
This is the first systematic review and meta-analysis of asso-
ciation studies between peripheral blood glutamate levels 
and MDD, and we demonstrated elevated glutamate levels 
in MDD in the pooled data set (529 patients with MDD and 
590 controls). A high level of heterogeneity was observed 
in this meta-analysis of all studies (I2=75.0%). To examine 
the sources of potential heterogeneity, we subsequently con-
ducted subgroup analyses and a meta-regression analysis.
In the subgroup analyses, we classified studies into 
those that involved the use of glutamate assays (HPLC or 
mass spectroscopy) and those that involved food consump-
tion (fasting or nonfasting). We also classified studies into 
groups based on ethnicity (Asian or non-Asian). We revealed 
significantly elevated glutamate levels in MDD with remark-
ably reduced levels of heterogeneity when we considered 
studies that involved only HPLC assays (SMD=0.41 and 
I2=28.5%), only fasting samples (SMD=0.33 and I2=0%), 
and only non-Asian samples (SMD=0.48 and I2=0%). These 
results suggest that the differences of glutamate assay, food 
consumption, and ethnicity might contribute to the hetero-
geneity observed in this study. On the other hand, subgroup 
analysis using studies involving medication-free samples 
showed significantly elevated glutamate levels in MDD with-
out reduction of heterogeneity level (I2=72.9%). However, 
these results from our subgroup analyses must be viewed 
with caution because of the small sample size.
In the meta-regression analysis, we found no signifi-
cant effects of age, gender, medication exposure, sample 
size, and publication year on blood glutamate levels in 
MDD patients. However, a significant decrease in blood 
glutamate levels has been reported in MDD after treat-
ment with antidepressants.11,12 Besides, a recent study 
showed significant positive correlations of daily doses 
of benzodiazepine derivatives and antidepressants with 
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Blood glutamate levels were significantly higher in MDD patients
suggest that medications, such as antidepressants and ben-
zodiazepines, may affect blood glutamate levels in MDD 
patients. In this meta-regression analysis of medication 
exposure, the sample size was small (only two studies17,24 
out of ten used medicated MDD samples), and we were 
unable to analyze the effect of medication in detail due to 
insufficient information on drugs used in these included 
studies. Further studies assessing the effects of medication 
on blood glutamate levels according to types and dosages 
of antidepressants will be needed.
Our study has several limitations. First, the sample size 
was relatively small. Second, there was high heterogeneity 
among the studies in this meta-analysis. Larger studies 
with detailed information on participants, such as severity 
of symptoms, existence of psychosis, types of antidepres-
sants and doses, and metabolic parameters, will be needed 
to validate our findings and reveal hidden factors that could 
explain the heterogeneity. Finally, it is still unclear whether 
peripheral blood glutamate levels can reflect brain levels of 
glutamate in MDD. Shulman et al38 examined the relation 
between plasma and medial prefrontal cortical glutamate 
levels in healthy male volunteers, and they found no cor-
relation between them. However, they measured glutamate 
levels in the limited brain region, and they assessed glu-
tamate levels of healthy subjects, not patients with MDD. 
Further studies will be needed to examine this relationship 
between them.
Conclusion
We conducted a systematic review and meta-analysis of asso-
ciation studies between peripheral blood glutamate levels and 
MDD, and we demonstrated elevated blood glutamate levels 
Figure 1 re meta-analysis of association studies between peripheral blood glutamate levels and MDD.
Abbreviations: re, random effect; MDD, major depressive disorder; sMD, standardized mean difference.
Figure 2 Publication bias assessed with funnel plot.
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in MDD. Our findings suggest that changes in glutamate lev-
els may be implicated in MDD and provide further support 
for the glutamatergic dysfunction hypothesis of MDD.
Acknowledgment
This work was supported in part by Japan Agency for Medical 
Research and Development, AMED (Tetsuro Ohmori), 
Grant-in-Aid for Scientific Research (C) (No 15K09809) 
(Shusuke Numata), and Grant-in-Aid for Young Scientists 
(B) (No 16K19769) (Shin-ya Watanabe).
Author contribution
Shusuke Numata designed the study. Tetsuro Ohmori and 
Shusuke Numata managed the research. Masatoshi Inoshita, 
Yukiko Tomioka, and Shin-ya Watanabe collected the 
data. Makoto Kinoshita, Masahito Nakataki, Atsushi Tajima, 
and Hidehiro Umehara undertook the statistical analysis. 
Masatoshi Inoshita, Masahito Nakataki, and Shusuke Numata 
wrote the draft. All authors contributed toward data analysis, 
drafting and critically revising the paper and agree to be 
accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey 
Replication. The epidemiology of major depressive disorder: results 
from the National Comorbidity Survey Replication (NCS-R). JAMA. 
2003;289(23):3095–3105.
2. Dean J, Keshavan M. The neurobiology of depression: an integrated 
view. Asian J Psychiatr. 2017;27:101–111.
3. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspec-
tives on new treatment strategies. Cell Physiol Biochem. 2013;31(6): 
761–777.
4. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic 
system to develop novel, improved therapeutics for mood disorders. 
Nat Rev Drug Discov. 2008;7(5):426–437.
5. Hashimoto K. Emerging role of glutamate in the pathophysiology of 
major depressive disorder. Brain Res Rev. 2009;61(2):105–123.
6. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signal-
ling in depression: progress and prospects. Nat Rev Drug Discov. 2017; 
16(7):472–486.
Table 2 results of subgroup analyses analysis of association studies between peripheral blood glutamate levels and MDD








p-value l2 (%) Q (p-value)
Blood sampling
Plasma 10 0.62 0.31 0.93 0.0001 75.9 2.9×10-4
serum 2 0.16 -0.12 0.45 0.26 0 0.42
glutamate assay
hPlc 8 0.41 0.22 0.60 ,0.0001 28.5 0.22
Ms 4 0.69 -0.069 1.45 0.075 89.7 ,1.0×10-4
Medication
Medication free 8 0.59 0.19 1.00 0.004 72.9 6.8×10-4
Food consumption
Fasting 4 0.33 0.063 0.59 0.015 0 0.51
Not fasting 3 0.90 0.031 1.77 0.042 94.1 ,1.0×10-4
ethnicity
asian 7 0.58 0.14 1.02 0.01 88.6 ,1.0×10-4
Non-asian 5 0.48 0.21 0.76 0.0006 0 0.84
Abbreviations: MDD, major depressive disorder; sMD, standardized mean difference; hPlc, high-performance liquid chromatography; Ms, mass spectroscopy.
Table 3 result of a meta-regression analysis in patients with MDD and controls








p-value l2 (%) Q (p-value)
age (mean year) 10 0.0078 -0.027 0.042 0.66 82.3 ,1.0×10-4
gender (% male) 11 0.0006 -0.018 0.019 0.95 79.7 ,1.0×10-4
Medication exposure  
(% medication-received patients)
10 -0.0018 -0.012 0.0083 0.73 74.8 1.2×10-4
sample size 12 -0.0012 -0.0041 0.0017 0.42 72.2 2.4×10-4
Published year 12 -0.0018 -0.035 0.032 0.92 77.3 ,1.0×10-4






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Blood glutamate levels were significantly higher in MDD patients
 7. Mlyniec K. Zinc in the glutamatergic theory of depression. Curr 
Neuropharmacol. 2015;13(4):505–513.
 8. Duman RS. Neuronal damage and protection in the pathophysiology 
and treatment of psychiatric illness: stress and depression. Dialogues 
Clin Neurosci. 2009;11(3):239–255.
 9. Hashimoto K. The role of glutamate on the action of antidepressants. Prog 
Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1558–1568.
 10. Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in pre-
clinical and/or mechanistic models of depression. Pharmacol Biochem 
Behav. 2012;100(4):688–704.
 11. Küçükibrahimoğlu E, Saygin MZ, Calişkan M, et al. The change 
in plasma GABA, glutamine and glutamate levels in fluoxetine- or 
S-citalopram-treated female patients with major depression. Eur J Clin 
Pharmacol. 2009;65(6):571–577.
 12. Maes M, Verkerk R, Vandoolaeghe E, et al. Serum levels of excitatory 
amino acids, serine, glycine, histidine, threonine, taurine, alanine and 
arginine in treatment-resistant depression: modulation by treatment with 
antidepressants and prediction of clinical responsivity. Acta Psychiatr 
Scand. 1998;97(4):302–308.
 13. Romeo B, Choucha W, Fossati P, et al. Meta-analysis of short- and 
mid-term efficacy of ketamine in unipolar and bipolar depression. 
Psychiatry Res. 2015;230(2):682–688.
 14. Umehara H, Numata S, Watanabe SY, et al. Altered KYN/TRP, 
Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma 
of medication-free patients with major depressive disorder. Sci Rep. 
2017;7(1):4855.
 15. Altamura CA, Mauri MC, Ferrara A, et al. Plasma and platelet excitatory 
amino acids in psychiatric disorders. Am J Psychiatry. 1993;150(11): 
1731–1733.
 16. Mauri MC, Ferrara A, Boscati L, et al. Plasma and platelet amino acid 
concentrations in patients affected by major depression and under 
fluvoxamine treatment. Neuropsychobiology. 1998;37(3):124–129.
 17. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma 
levels of glutamate, alanine and serine with severity of depression. Prog 
Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1155–1158.
 18. Woo HI, Chun MR, Yang JS, et al. Plasma amino acid profiling in major 
depressive disorder treated with selective serotonin reuptake inhibitors. 
CNS Neurosci Ther. 2015;21(5):417–424.
 19. Ogawa S, Koga N, Hattori K, et al. Plasma amino acid profile in major 
depressive disorder: analyses in two independent case-control sample 
sets. J Psychiatr Res. 2018;96:23–32.
 20. Altamura C, Maes M, Dai J, et al. Plasma concentrations of excitatory 
amino acids, serine, glycine, taurine and histidine in major depression. 
Eur Neuropsychopharmacol. 1995;(5 Suppl):71–75.
 21. Xu HB, Fang L, Hu ZC, et al. Potential clinical utility of plasma 
amino acid profiling in the detection of major depressive disorder. 
Psychiatry Res. 2012;200(2–3):1054–1057.
 22. Mayoral-Mariles A, Cruz-Revilla C, Vega-Manriquez X, et al. Plasma 
amino acid levels discriminate between control subjects and mildly 
depressed elderly women. Arch Med Res. 2012;43(5):375–382.
 23. Lu YR, Fu XY, Shi LG, et al. Decreased plasma neuroactive amino 
acids and increased nitric oxide levels in melancholic major depressive 
disorder. BMC Psychiatry. 2014;14:123.
 24. Hashimoto K, Yoshida T, Ishikawa M, et al. Increased serum levels of 
serine enantiomers in patients with depression. Acta Neuropsychiatr. 
2016;28(3):173–178.
 25. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from 
patients with mood disorders. Biol Psychiatry. 2007;62(11):1310–1316.
 26. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific 
alterations of gamma-aminobutyric acid and glutamate in patients with 
major depression. Arch Gen Psychiatry. 2004;61(7):705–713.
 27. Arnone D, Mumuni AN, Jauhar S, et al. Indirect evidence of selective 
glial involvement in glutamate-based mechanisms of mood regulation 
in depression: meta-analysis of absolute prefrontal neuro-metabolic 
concentrations. Eur Neuropsychopharmacol. 2015;25(8):1109–1117.
 28. Levine J, Panchalingam K, Rapoport A, et al. Increased cerebrospinal 
fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47(7): 
586–593.
 29. Hashimoto K, Bruno D, Nierenberg J, et al. Abnormality in glutamine-
glutamate cycle in the cerebrospinal fluid of cognitively intact elderly 
individuals with major depressive disorder: a 3-year follow-up study. 
Transl Psychiatry. 2016;6:e744.
 30. Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate 
and glycine in refractory affective disorder. Biol Psychiatry. 2007; 
61(10):162–166.
 31. Garakani A, Martinez JM, Yehuda R, et al. Cerebrospinal fluid levels 
of glutamate and corticotropin releasing hormone in major depression 
before and after treatment. J Affect Disord. 2013;146(2):262–265.
 32. Nishi A, Numata S, Tajima A, et al. Meta-analyses of blood homo-
cysteine levels for gender and genetic association studies of the MTHFR 
C677T polymorphism in schizophrenia. Schizophr Bull. 2014;40(5): 
1154–1163.
 33. Tomioka Y, Numata S, Kinoshita M, et al. Decreased serum pyridoxal 
levels in schizophrenia: meta-analysis and Mendelian randomization 
analysis. J Psychiatry Neurosci. 2018;43(2):170053.
 34. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard 
deviation from the sample size, median, range and/or interquartile range. 
BMC Med Res Methodol. 2014;14:135.
 35. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency 
in meta-analyses. BMJ. 2003;327(7414):557–560.
 36. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis 
detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
 37. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-
study heterogeneity in meta-analysis: proposed metrics and empirical 
evaluation. Int J Epidemiol. 2008;37(5):1148–1157.
 38. Shulman Y, Grant S, Seres P, et al. The relation between peripheral and 







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1













Table S1 result of leave-one-out sensitivity analysis




p-value I2 (%) Q (p-value)
altamura et al,1 1993 0.52 0.25 0.80 2.2×10-4 76.9 1.2×10-4
altamura et al,2 1995 0.56 0.26 0.85 2.4×10-4 78.1 ,1.0×10-4
Mauri et al,3 1998 0.54 0.24 0.84 3.7×10-4 78.0 ,1.0×10-4
Maes et al,4 1998 0.56 0.26 0.86 2.1×10-4 78.0 ,1.0×10-4
Mitani et al,5 2006 0.51 0.22 0.79 4.5×10-4 75.4 3.3×10-4
Xu et al,6 2012 0.59 0.31 0.87 ,1.0×10-4 75.0 2.1×10-4
Mayoral-Mariles et al,7 2012 0.56 0.27 0.86 2.0×10-4 77.8 ,1.0×10-4
Woo et al,8 2015 0.57 0.27 0.87 1.9×10-4 77.5 ,1.0×10-4
hashimoto et al,9 2016 0.60 0.31 0.88 ,1.0×10-4 72.7 5.5×10-4
Umehara et al,10 2017 0.40 0.24 0.55 ,1.0×10-4 22.3 0.22
Ogawa et al,11 2018. sample set a 0.57 0.27 0.88 2.2×10-4 72.8 1.4×10-4
Ogawa et al,11 2018. sample set B 0.54 0.24 0.84 4.9×10-4 77.0 1.1×10-4
Abbreviation: sMD, standardized mean difference.
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